Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Nkarta, Inc. Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights May 09, 2024 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Announces Pricing of $240 Million Underwritten Offering March 25, 2024 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition December 09, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights November 09, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis October 17, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures October 16, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights August 10, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia June 27, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program June 26, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma June 10, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights May 11, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting April 17, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights March 16, 2023 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma December 05, 2022 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights November 09, 2022 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting November 07, 2022 From Nkarta, Inc. Via GlobeNewswire Tickers NKTX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.